Cannabis Treatment Demands Overwhelm EU Health Services

Based on the European Drug Report 2025 by the European Union Drugs Agency (EUDA), European cannabis use remains the most significant illicit drug challenge across the continent, presenting unprecedented demands on public health systems and communities. The comprehensive data reveals concerning trends that highlight the urgent need for enhanced prevention strategies and treatment approaches.

Cannabis Consumption Reaches Record Levels

European cannabis use has reached troubling proportions throughout the continent, with an estimated 8.4% of European adults (24 million people aged 15-64) having used cannabis in the past year. Among younger demographics, the statistics are particularly alarming: 18.6% of 15-24 year-olds used cannabis in the last year, while 10.1% used it within the past month.

The implications of widespread cannabis consumption are becoming increasingly evident. Around 1.5% of adults in the European Union (4.3 million people) are daily or almost daily cannabis consumers, representing the population most likely to experience serious health complications. These individuals face heightened risks of developing cannabis dependence, chronic respiratory symptoms, and psychotic symptoms.

Treatment Systems Overwhelmed by Cannabis Demands

Cannabis treatment programs across Europe are experiencing unprecedented demand due to rising European cannabis use patterns. The substance accounts for more than one-third of all drug treatment admissions, rising to over two-fifths when considering first-time treatment entrants. This surge in cannabis treatment needs reflects the growing recognition of problematic cannabis consumption as a serious public health concern.

Treatment demographics reveal concerning patterns. The majority of those entering cannabis treatment for the first time are men (81%), though the proportion of women has increased from 16% in 2018 to 19% in 2023. Perhaps most troubling is the increasing delay between initial use and seeking help – men now enter treatment 12 years after starting cannabis use, while women wait 10 years.

Rising Potency Amplifies Health Risks

The potency of cannabis products has reached historically high levels, significantly amplifying risks associated with European cannabis use. In 2023, the average THC content of cannabis resin increased to 23%, more than double that of herbal cannabis at 11%. This dramatic increase in potency over the past decade correlates with more severe health outcomes, particularly when associated with early onset cannabis consumption.

High-potency cannabis products are increasingly linked to acute drug-toxicity presentations in hospital emergency departments. Cannabis was involved in 46% of drug-related emergency cases in Spain and 9% of acute intoxication cases in Germany during 2022.

New Synthetic Cannabis Products Emerge

The cannabis market is evolving rapidly with the introduction of semi-synthetic cannabinoids that present unknown health risks. Substances like hexahydrocannabinol (HHC), hexahydrocannabiphorol (HHC-P), and tetrahydrocannabiphorol (THCP) have appeared in commercial markets across several EU Member States.

These new products have already caused concerning incidents. Between June 2022 and February 2024, Czechia’s Toxicology Information Centre recorded over 170 consultations related to HHC, many involving young people and children who consumed edible products. Hungary reported 30 acute non-fatal poisonings associated with synthetic cannabinoid-containing products in June 2024.

Environmental and Social Costs Mount

Large-scale cannabis cultivation operations across Europe generate substantial environmental impacts to support European cannabis use demands. Illicit cannabis cultivation requires intensive water and energy resources, contributing to carbon footprint concerns, soil erosion, and depletion of water reserves. Law enforcement agencies dismantle thousands of cultivation sites annually, ranging from small-scale operations to industrial-sized facilities.

The illegal cannabis trade generates sizeable profits for organized crime groups, contributing to unprecedented levels of drug market-related violence in several EU Member States. Criminal networks operating in this market are increasingly diverse and adaptable, often associated with violence, corruption, and misuse of legal business structures.

Cannabis Treatment Approaches Require Enhancement

Current cannabis treatment options show mixed effectiveness in addressing problematic cannabis consumption, highlighting the need for improved intervention strategies. Psychosocial treatments, including cognitive behavioral therapy and motivational interviewing, represent the most well-researched interventions for cannabis problems. However, no approved pharmacological treatment currently exists.

Online interventions became more widely available during the COVID-19 pandemic, with evidence suggesting women may benefit more from these approaches. Programs integrating sessions with trained therapists appear to have stronger treatment effects than fully automated interventions.

Regional Variations in Cannabis Consumption Patterns

Wastewater analysis reveals significant regional differences in European cannabis use across cities. Cannabis consumption was highest in western and southern European cities, particularly in Spain, the Netherlands, Portugal, and Norway. Of 51 cities monitored, 13 reported increases in cannabis metabolites while 25 showed decreases between 2023 and 2024.

School survey data from the 2024 ESPAD study indicates that 15-16 year-old students perceive cannabis as the easiest illicit substance to obtain, with 30% rating it as easily obtainable. This accessibility contributes to early onset cannabis consumption, which research links to more severe long-term health risks.

Trafficking Routes Continue to Diversify

Cannabis trafficking methods are becoming increasingly sophisticated to meet consumption demands, creating challenges for interdiction efforts. Seizures through postal systems and commercial air travel are rising, with products originating from various countries including the United States, Canada, and Thailand. Spain continues to play a significant role as both a transit country and production area, accounting for 68% of all cannabis resin seized in the European Union.

Prevention Strategies Must Address Emerging Challenges

The evolving cannabis landscape requires comprehensive prevention approaches that address both traditional and emerging forms of the substance. Educational initiatives must highlight the intensifying health risks associated with high-potency products and new synthetic variants.

Early intervention programs targeting adolescents show promise, particularly those addressing the 2.6% of students who report first cannabis use at age 13 or younger. These prevention efforts must account for the decreasing gender gap in European cannabis use, with lifetime cannabis use among 15-16 year-olds now at 14% for boys and 12% for girls.

Healthcare Systems Need Enhanced Capacity

The increasing demand for cannabis treatment requires healthcare systems to expand capacity and improve referral pathways to address rising consumption patterns. Currently, criminal justice and healthcare systems account for about one quarter of cannabis treatment referrals, while 45% of clients enter treatment on their own initiative.

Better understanding is needed of the problems experienced by people with problematic European cannabis use and the development of appropriate, evidence-based treatment options. The wide variety of interventions currently provided, from brief interventions to directive referrals from criminal justice systems, highlights the need for standardized, effective approaches to cannabis treatment.

Health Systems Under Strain

European cannabis markets are changing rapidly. With 24 million adults using cannabis annually and treatment centers handling over 106,000 cases in 2023, the scale of the challenge is clear. People now wait over a decade between first use and seeking treatment – a delay that has widened significantly since 2018.

Cannabis resin potency has doubled to 23% THC while new synthetic variants create unpredictable health episodes. Spain seized 375 tonnes of resin in 2023 as criminal networks shift to postal systems and commercial flights. Treatment approaches show promise through cognitive behavioral therapy, though no pharmaceutical options exist.

European health systems face mounting pressure as European cannabis use evolves faster than responses can adapt.

Source: EUDA